The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Forced Vital Capacity in Idiopathic Pulmonary Fibrosis — FDA Review of Pirfenidone and Nintedanib
Abstract
In 2014, the FDA approved two drugs for idiopathic pulmonary fibrosis that posed a regulatory challenge: the primary efficacy variable studied was the change in forced vital capacity, which hadn't been established as a surrogate for clinically meaningful benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Changes in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials
Raghu, G., Collard, H. R., Anstrom, K. J., Flaherty, K. R., Fleming, T. R., King, T. E., Martinez, F. J., & Brown, K. K. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201201-0006pp · Cited by 242
Cited by
Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
NTRK fusion-positive cancers and TRK inhibitor therapy
Cocco, E., Scaltriti, M., & Drilon, A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0113-0 · Cited by 1,485
Martinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., Swigris, J. J., Taniguchi, H., & Wells, A. U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.74 · Cited by 1,388
Spectrum of fibrotic lung diseases
Wijsenbeek, M., & Cottin, V. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2005230 · Cited by 736
Maher, T. M., Corte, T. J., Fischer, A., Kreuter, M., Lederer, D. J., Molina-Molina, M., Axmann, J., Kirchgaessler, K.-U., Samara, K., Gilberg, F., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30341-8 · Cited by 629
Cellular mechanotransduction in health and diseases: from molecular mechanism to therapeutic targets
Di, X., Gao, X., Peng, L., Ai, J., Jin, X., Qi, S., Li, H., Wang, K., & Luo, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01501-9 · Cited by 622
Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications
Weiskirchen, R., Weiskirchen, S., & Tacke, F. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.003 · Cited by 538
Richeldi, L., Cottin, V., du Bois, R. M., Selman, M., Kimura, T., Bailes, Z., Schlenker-Herceg, R., Stowasser, S., & Brown, K. K. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.02.001 · Cited by 463
Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review
Raghu, G., Amatto, V. C., Behr, J., & Stowasser, S. (2015) · European Respiratory Journal · doi:10.1183/13993003.02316-2014 · Cited by 463
Alveolar Epithelial Type II Cells as Drivers of Lung Fibrosis in Idiopathic Pulmonary Fibrosis
Parimon, T., Yao, C., Stripp, B. R., Noble, P. W., & Chen, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072269 · Cited by 375
Jun, J.-I., & Lau, L. F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93563 · Cited by 345
Raghu, G., Brown, K. K., Collard, H. R., Cottin, V., Gibson, K. F., Kaner, R. J., Lederer, D. J., Martinez, F. J., Noble, P. W., Song, J. W., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30421-0 · Cited by 278
Maher, T. M., Tudor, V. A., Saunders, P., Gibbons, M. A., Fletcher, S. V., Denton, C. P., Hoyles, R. K., Parfrey, H., Renzoni, E. A., Kokosi, M., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00359-9 · Cited by 290
The next generation of therapeutics for chronic kidney disease
Breyer, M. D., & Susztak, K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.67 · Cited by 272
TGF-β signaling in the kidney: profibrotic and protective effects
Sureshbabu, A., Muhsin, S. A., & Choi, M. E. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00365.2015 · Cited by 267
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Maher, T. M., & Strek, M. E. (2019) · Respiratory Research · doi:10.1186/s12931-019-1161-4 · Cited by 265
Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis
Russell, A.-M., Adamali, H., Molyneaux, P. L., Lukey, P. T., Marshall, R. P., Renzoni, E. A., Wells, A. U., & Maher, T. M. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201511-2152oc · Cited by 178
Povedano, J. M., Martinez, P., Serrano, R., Tejera, Á., Gómez-López, G., Bobadilla, M., Flores, J. M., Bosch, F., & Blasco, M. A. (2018) · eLife · doi:10.7554/elife.31299 · Cited by 139
Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years
Raghu, G. (2017) · European Respiratory Journal · doi:10.1183/13993003.01209-2017 · Cited by 146
Home monitoring in interstitial lung diseases
Wijsenbeek, M. S., Moor, C. C., Johannson, K. A., Jackson, P. D., Khor, Y. H., Kondoh, Y., Rajan, S. K., Tabaj, G. C., Varela, B. E., van der Wal, P., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00228-4 · Cited by 98
Matrix biomechanics and dynamics in pulmonary fibrosis
Haak, A. J., Tan, Q., & Tschumperlin, D. J. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.004 · Cited by 95
Telomerase treatment prevents lung profibrotic pathologies associated with physiological aging
Piñeiro-Hermida, S., Autilio, C., Martínez, P., Bosch, F., Pérez-Gil, J., & Blasco, M. A. (2020) · Journal of Cell Biology · doi:10.1083/jcb.202002120 · Cited by 60
Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy
Leuschner, G., Stocker, F., Veit, T., Kneidinger, N., Winter, H., Schramm, R., Weig, T., Matthes, S., Ceelen, F., Arnold, P., et al. (2018) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2017.07.002 · Cited by 59
Zhang, Y., MacKenzie, B., Koleng, J. J., Maier, E., Warnken, Z. N., & Williams, R. O. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01085 · Cited by 27
Zheng, Y., Schupp, J., Adams, T., Clair, G., Justet, A., Ahangari, F., Yan, X., Hansen, P., Carlon, M., Cortesi, E., et al. (2023) · doi:10.21203/rs.3.rs-3676579/v1 · Cited by 34
Metadata
- Authors
- Karimi-Shah, B. A., & Chowdhury, B. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-03-26
- Volume
- 372
- Issue
- 13
- Pages
- 1189-1191
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2315538569
- Cited by
- 316
- References
- 2
- FWCI
- 28.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.